Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROV045
- Development stage
- Preclinical
- Lead developer
- Vektor Pharma
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
ROV045 is a proprietary transdermal delivery system (TDS) formulation of rotigotine, a non-ergoline dopamine agonist, developed by XPhyto Therapeutics through its subsidiary Vektor Pharma TF. The drug is designed as a once-daily patch for the treatment of Parkinson's disease and restless legs syndrome (RLS). It utilizes a specialized platform technology to deliver rotigotine continuously through the skin over a 24-hour period. Preclinical in-vitro and ex-vivo studies have demonstrated that ROV045 possesses dissolution and absorption profiles comparable to the reference listed drug, Neupro. As of late 2022, the formulation was positioned for entry into human clinical trials to establish bioequivalence.
- Other names
- rotigotine transdermal delivery systemrotigotine TDS
Beyond the preview
Go deeper on ROV045.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROV045.